KPC Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People's Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals, Inc. was founded in 1951 and is based in Kunming, the People's Republic of China.

KPC Pharmaceuticals, Inc.

KPC Pharmaceuticals is a Chinese pharmaceutical company that manufactures and develops pharmaceutical products with a focus on international markets.

KPC Pharmaceuticals

KPC Pharmaceuticals, Inc 昆药集团股份有限公司 | 214 followers on LinkedIn. KPC is a pharmaceutical company which focused on innovative natural botanical drugs. | KPC Pharmaceuticals, Inc (hereinafter be abbreviated as ‘KPC’, 600422 SH) was established in March 1951 and floated on the Shanghai Stock Exchange in December 2000. With its considerable professional experience in pharmaceutical industry, the company is listed as one of the new key national high-tech companies and one of the Top 100 companies in the Chinese medical industry. The company’s brands such as Luotai®, Tianxuanqing®, Artemedine®, Artem® and Arco® currently enjoy a good reputation both at home and abroad.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue							8.12B -	7.72B 4.96%			7.63B -
cost of revenue				3.13B -			4.17B -	4.33B 4.00%			4.35B -
gross profit							3.95B -	3.38B 14.41%			3.28B -
selling and marketing expenses							2.98B -	2.35B 21.06%			2.43B -
general and administrative expenses							102.27M -	120.17M 17.49%			76.79M -
selling general and administrative expenses							3.08B -	2.47B 19.78%			2.71B -
research and development expenses							83.51M -	128.45M 53.81%			63.87M -
other expenses	17.95M -	26.57M 47.96%	41.08M 54.63%	57.43M 39.80%	-3.98M 106.93%	-2.68M 32.77%	228.60M 8,643.38%	238.81M 4.46%	240.39M 0.66%	239.23M 0.48%	-42.96M 117.96%
cost and expenses							7.56B -	7.17B 5.13%			7.16B -
operating expenses	754.79M -	894.03M 18.45%	1.21B 35.58%	1.57B 29.14%	2.19B 39.89%	3.11B 42.04%	3.39B 9.09%	2.84B 16.34%	2.83B 0.21%	2.82B 0.30%	2.81B 0.43%
interest expense							40.41M -	29.16M 27.84%			24.38M -
ebitda							733.73M -	703.79M 4.08%			684.88M -
operating income							539.80M -	540.83M 0.19%			471.26M -
depreciation and amortization							193.93M -	162.96M 15.97%			213.63M -
total other income expenses net							4.63M -				92.55M -
income before tax							544.43M -	540.49M 0.72%			563.81M -
income tax expense							76.68M -	78.30M 2.12%			109.48M -
net income	231.62M -	292.24M 26.17%	420.85M 44.01%	407.26M 3.23%	330.10M 18.95%	335.54M 1.65%	454.31M 35.40%	456.86M 0.56%	507.67M 11.12%	383.18M 24.52%	444.68M 16.05%
weighted average shs out	650.81M -	788.74M 21.19%	788.70M 0.00%	788.64M 0.01%	785.76M 0.37%	768.87M 2.15%	761.37M 0.98%	759.15M 0.29%	757.71M 0.19%	759.15M 0.19%	758.09M 0.14%
weighted average shs out dil	650.81M -	788.74M 21.19%	788.70M 0.00%	788.64M 0.01%	785.76M 0.37%	768.52M 2.19%	761.63M 0.90%	759.15M 0.33%	757.71M 0.19%	759.15M 0.19%	758.09M 0.14%
eps	0.36 -	0.37 2.78%	0.53 43.24%	0.52 1.89%	0.42 19.23%	0.44 4.76%	0.60 36.36%	0.60 0%	0.67 11.67%	0.50 25.37%	0.59 18.00%
epsdiluted	0.36 -	0.37 2.78%	0.53 43.24%	0.52 1.89%	0.42 19.23%	0.44 4.76%	0.60 36.36%	0.60 0%	0.67 11.67%	0.50 25.37%	0.59 18.00%

6004

CN:COM:KPC

KPC Pharmaceuticals

Last Close

15.08

22/11 07:00

Market Cap

12.73B

Beta: -

Volume Today

14.99M

Avg: -

Preview